The Oncosearch | Oncotarget

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Christie P.M. Verkleij, Kristine A. Frerichs, Marloes Broekmans, Saida Absalah, Patricia W.C. Maas-Bosman, Sandy Kruyswijk, Inger S. Nijhof, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk

Published Oct 24, 2020 · Vol. 11, No. 45 · pp. 4076-4081

Keywords: multiple myeloma, bispecific antibody, immunotherapy, BCMA, CD38

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

Michael E. Clark, Helen Rizos, Michelle R. Pereira, Ashleigh C. McEvoy, Gabriela Marsavela, Leslie Calapre, Katie Meehan, Olivia Ruhen, Muhammad A. Khattak, Tarek M. Meniawy, Georgina V. Long, Matteo S. Carlino, Alexander M. Menzies, Michael Millward, Melanie Ziman, Elin S. Gray

Published Oct 22, 2020 · Vol. 11, No. 44 · pp. 4016-4027

Keywords: melanoma, targeted therapy, drug resistance, BRAF splicing, extracellular vesicles

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes Review

Vic Hart, Hannah Gautrey, John Kirby, Alison Tyson-Capper

Published Oct 22, 2020 · Vol. 11, No. 46 · pp. 4338-4357

Keywords: HER2, Δ16-HER2, splice variant, breast cancer, trastuzumab

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

Douglas B. Johnson, Caroline A. Nebhan, Marcus S. Noel

Published Oct 22, 2020 · Vol. 11, No. 44 · pp. 3900-3903

Keywords: trametinib, MEK, BRAF, atypical, fusion

HIC1 (Hypermethylated in Cancer 1) modulates the contractile activity of prostate stromal fibroblasts and directly regulates CXCL12 expression Research Paper

Marion Dubuissez, Sonia Paget, Souhila Abdelfettah, Nathalie Spruyt, Vanessa Dehennaut, Gaylor Boulay, Ingrid Loison, Clementine de Schutter, Brian R. Rood, Martine Duterque-Coquillaud, Xavier Leroy, Dominique Leprince

Published Oct 21, 2020 · Vol. 11, No. 45 · pp. 4138-4154

Keywords: HIC1, CXCL12, SDF1, α-SMA, Acta2

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Niraj Lodhi, Moe Tun, Poonam Nagpal, Arati A. Inamdar, Nehad M. Ayoub, Noor Siyam, Lucia Oton-Gonzalez, Angela Gerona, Dainelle Morris, Rana Sandhu, Kwangsun Stephen Suh

Published Oct 20, 2020 · Vol. 11, No. 44 · pp. 4045-4073

Keywords: DLBCL, diagnosis, R-CHOP, precision medicine, prognosis

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, Hibiki Akashi, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

Published Oct 7, 2020 · Vol. 11, No. 44 · pp. 3984-3997

Keywords: pan-RAF inhibitor, Bim, FOXO3a, bortezomib, lenalidomide

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model Research Paper

Robert A. Kazmierczak, Bakul Dhagat-Mehta, Elke Gulden, Li Lee, Lixin Ma, Clintin P. Davis-Stober, Austen A. Barnett, Chiswili Yves Chabu

Published Oct 4, 2020 · Vol. 11, No. 44 · pp. 3943-3958

Keywords: salmonella, cancer targeting, prostate cancer, immunotherapy, TRAMP

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Nathan M. Merrill, Nathalie M. Vandecan, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Sofia D. Merajver, Matthew B. Soellner

Published Oct 3, 2020 · Vol. 11, No. 44 · pp. 3921-3932

Keywords: bladder cancer, drug screen, 3D culture, basal bladder cancer, MEK inhibition

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis Research Paper

Myoung Sook Kim, Ramkishore Gernapudi, Yessenia Cedeño Cedeño, Brian M. Polster, Ramon Martinez, Paul Shapiro, Santosh Kesari, Elmar Nurmemmedov, Antonino Passaniti

Published Sep 3, 2020 · Vol. 11, No. 43 · pp. 3863-3885

Keywords: mitochondrial ATP synthase, oxygen consumption rate, ATP synthesis, reactive oxygen species,

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy Research Paper

Wojciech Dawicki, Kevin J.H. Allen, Ravendra Garg, Eileen M. Geoghegan, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova

Published Aug 26, 2020 · Vol. 11, No. 39 · pp. 3571-3581

Keywords: anti-CD45 targeted lymphodepletion, radioimmunotherapy, adoptive cell therapy, 131Iodine, 177Lutetium

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Review

Fleury Augustin Nsole Biteghe, Neelakshi Mungra, Nyangone Ekome Toung Chalomie, Jean De La Croix Ndong, Jean Engohang-Ndong, Guillaume Vignaux, Eden Padayachee, Krupa Naran, Stefan Barth

Published Aug 26, 2020 · Vol. 11, No. 38 · pp. 3531-3557

Keywords: epidermal growth factor receptor (EGFR), recombinant immunotoxins (ITs), targeted human cytolytic fusion proteins (hCFPs), recombinant antibody-drug conjugates (rADCs), recombinant antibody photoimmunoconjugates (rAPCs)

A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Research Paper

Erryk S. Katayama, Jonathan J. Hue, David L. Bajor, Lee M. Ocuin, John B. Ammori, Jeffrey M. Hardacre, Jordan M. Winter

Published Aug 24, 2020 · Vol. 11, No. 38 · pp. 3489-3501

Keywords: pancreatic cancer, pancreatic ductal adenocarcinoma, clinical trial, novel treatment, drug development

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo Research Paper

Tiziano Ongaro, Baptiste Gouyou, Marco Stringhini, Riccardo Corbellari, Dario Neri, Alessandra Villa

Published Aug 23, 2020 · Vol. 11, No. 41 · pp. 3698-3711

Keywords: tumor targeting, fibronectin, immunocytokines, interleukin-2, protein engineering

Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements Research Paper

Adélia Mendes, Ramona Jühlen, Valérie Martinelli, Birthe Fahrenkrog

Published Aug 11, 2020 · Vol. 11, No. 36 · pp. 3371-3386

Keywords: CRM1, NUP214, leukemia, nuclear export, nucleoporin

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

Rod Balhorn, Monique Cosman Balhorn

Published Aug 5, 2020 · Vol. 11, No. 35 · pp. 3315-3349

Keywords: HLA-DR, selective high affinity ligand, SH7139, SH7129, solid cancers

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy Case Report

Matteo Torresetti, Donatella Brancorsini, Francesca Morgese, Valeria Cognigni, Alessandro Scalise, Rossana Berardi, Giovanni Di Benedetto

Published Jul 30, 2020 · Vol. 11, No. 34 · pp. 3256-3262

Keywords: sarcomatoid melanoma, giant melanoma, BRAF mutation, targeted therapy, next-generation sequencing

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL Research Paper

Yaya Chu, Aradhana Awasthi, Sanghoon Lee, Dina Edani, Changhong Yin, Jessica Hochberg, Tishi Shah, Tae-Hoon Chung, Janet Ayello, Carmella van de Ven, Christian Klein, Dean Lee, Mitchell S. Cairo

Published Jul 21, 2020 · Vol. 11, No. 32 · pp. 3035-3047

Keywords: Obinutuzumab, rituximab, survival, primary mediastinal large B-cell lymphoma, antibody-dependent cellular cytotoxicity

The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL) Research Paper

Stefan Nagel, Claudia Pommerenke, Roderick A.F. MacLeod, Corinna Meyer, Maren Kaufmann, Hans G. Drexler

Published Jul 15, 2020 · Vol. 11, No. 34 · pp. 3208-3226

Keywords: homeobox, NKL-code, T-ALL, LL-100, Th17

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer Research Paper

Oliver J. Pickles, Aneta Drozd, Louise Tee, Andrew D. Beggs, Gary W. Middleton

Published Jul 13, 2020 · Vol. 11, No. 34 · pp. 3188-3197

Keywords: colorectal cancer, BRAF, paradox breaker, encorafenib, PLX8394

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes Review

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

HIC1 (Hypermethylated in Cancer 1) modulates the contractile activity of prostate stromal fibroblasts and directly regulates CXCL12 expression Research Paper

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model Research Paper

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis Research Paper

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy Research Paper

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Review

A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Research Paper

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo Research Paper

Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements Research Paper

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy Case Report

The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL) Research Paper

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes Review

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

HIC1 (Hypermethylated in Cancer 1) modulates the contractile activity of prostate stromal fibroblasts and directly regulates CXCL12 expression Research Paper

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma Research Paper

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model Research Paper

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis Research Paper

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy Research Paper

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Review

A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Research Paper

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo Research Paper

Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements Research Paper

Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers Research Paper

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy Case Report

The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL) Research Paper

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer Research Paper